Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Depreciation & Amortization - Total: 2012-2024

Historic Depreciation & Amortization - Total for Ani Pharmaceuticals (ANIP) over the last 13 years, with Dec 2024 value amounting to $7.4 million.

  • Ani Pharmaceuticals' Depreciation & Amortization - Total rose 8.33% to $1.3 million in Q4 2020 from the same period last year, while for Dec 2020 it was $4.9 million, marking a year-over-year increase of 6.52%. This contributed to the annual value of $7.4 million for FY2024, which is 1.33% down from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Depreciation & Amortization - Total of $7.4 million as of FY2024, which was down 1.33% from $7.5 million recorded in FY2023.
  • Ani Pharmaceuticals' Depreciation & Amortization - Total's 5-year high stood at $7.5 million during FY2023, with a 5-year trough of $4.8 million in FY2020.
  • Its 3-year average for Depreciation & Amortization - Total is $7.4 million, with a median of $7.4 million in 2024.
  • In the last 5 years, Ani Pharmaceuticals' Depreciation & Amortization - Total soared by 34.55% in 2022 and then dropped by 1.33% in 2024.
  • Ani Pharmaceuticals' Depreciation & Amortization - Total (Yearly) stood at $4.8 million in 2020, then rose by 14.58% to $5.5 million in 2021, then surged by 34.55% to $7.4 million in 2022, then increased by 1.35% to $7.5 million in 2023, then fell by 1.33% to $7.4 million in 2024.